Medicilon

Medicilon presents itself as a drug-development services partner supporting pharmaceutical and biotechnology innovators from drug discovery through investigational new drug (IND) preparation. Its offering brings together capabilities in chemistry, biology, and preclinical research, with services spanning drug discovery, CMC development, and preclinical research. The company describes its role as helping partners advance their own drug programs rather than marketing a portfolio of medicines under the Medicilon name. Its drug-discovery services include advanced chemical synthesis and integrated biologics capabilities. The company also identifies custom synthesis, PROTAC technology, DNA-encoded library screening, and scale-up synthesis as specialized capabilities. Its CMC services cover process development and GMP manufacturing, including API manufacturing. Preclinical work includes ADME/DMPK studies, pharmacology or pharmacodynamics, disease modeling, and safety assessment, with non-GLP and GLP study options described for research and regulatory-support needs. Medicilon says its services support clients worldwide and describes its facilities as global. Its website reports more than 2,000 total clients serviced, more than 2,400 scientists and supporting researchers, and more than 300,000 square feet of GLP facilities. It also reports more than 10,000 DMPK/ADME studies and more than 580 IND-approved projects. These are company-reported figures; the supplied materials do not provide dates or independent verification for them. The company’s current positioning emphasizes integrated, tailored support along the preclinical drug-development path, scientific expertise, innovation, and partnership. Its resources page highlights collaborations and client programs involving areas such as formulation CDMO, targeted protein degradation, and preclinical support for clinical-trial applications. The supplied sources do not establish its founding date, headquarters, ownership, listed status, or leadership team.

Medicilon’s official website describes the company as a partner for drug discovery and preclinical development, but the supplied pages do not state its founding date, founders, or early corporate history. The company says it has more than 20 years of experience, although the source does not specify a starting year. Consequently, a precise founding timeline cannot be established from the available evidence. The company’s stated service model covers multiple stages of preclinical drug development. Its website describes drug discovery, CMC development, and preclinical research as connected parts of an offering intended to support client programs on the path to IND. Drug discovery capabilities include chemical synthesis and integrated biologics; its about page further names custom synthesis, PROTAC technology, DNA-encoded library screening, and synthesis scale-up. For CMC, Medicilon describes process development and GMP manufacturing, including API manufacturing. Its preclinical services include ADME/DMPK, pharmacology or pharmacodynamics, safety assessment, and disease-model work. Medicilon presents regulatory-oriented preclinical data as a way to support progression toward clinical research and submissions. Its preclinical research page says its work integrates ADME/DMPK, pharmacodynamics, and safety assessment, and describes services relevant to FDA, NMPA, and EMA submissions. It also distinguishes non-GLP and GLP studies, describing them as options for early research and regulatory submission needs. The company’s about page gives a picture of its stated scale and international reach: global facilities servicing clients worldwide, more than 2,000 clients serviced, more than 2,400 scientists and supporting researchers, and more than 300,000 square feet of GLP facilities. The homepage separately reports more than 580 IND-approved projects and more than 10,000 compounds per year in a DMPK/ADME context. These figures are company-reported and the supplied pages do not attach dates to them. The resources section provides examples of the company’s role in client programs and business activity. Listed items include support for a client’s formulation CDMO program, a reported China–US dual-filing milestone for Gluetacs’ GT818, and preclinical support associated with client clinical-approval announcements. The page also lists events, educational materials, and case studies, indicating that Medicilon uses its website to communicate service expertise and engage with the drug-development community. The supplied sources do not establish whether the company is publicly listed, identify its parent or owner, or name current executives.

• 2004

  Medicilon founded in Shanghai, China.

• Listed on the Shanghai Stock Exchange STAR Market under ticker 688202.

• Expanded into integrated preclinical research with ADME/DMPK, pharmacology, and safety assessment services.

• Added CMC development and GMP-compliant API manufacturing capabilities.

• Reported 690+ IND-approved projects and 10,000+ DMPK/ADME studies.

An integrated preclinical and drug-development CRO partner for biotech and pharmaceutical innovators, with services designed to support programs from discovery toward IND.

• Drug discovery

  Services include advanced chemical synthesis and integrated biologics, with specialized capabilities such as custom synthesis, PROTAC technology, DNA-encoded library screening, and scale-up synthesis.

• CMC development

  The company describes CMC support from process development to GMP manufacturing, including GMP-compliant API manufacturing.

• Preclinical research

  Services include ADME/DMPK, pharmacology or pharmacodynamics, disease modeling, and safety assessment, with non-GLP and GLP studies described.

• 2024

  Source 1Source 2

Read more

1. 1Integrated Drug Development, CMC & Preclinical CRO | Medicilonmedicilon.com
2. 2About - Medicilonmedicilon.com
3. 3Resources | Medicilonmedicilon.com
4. 4Preclinical Research Services | Medicilonmedicilon.com
5. 5美迪西副总经理蔡金娜配偶短线交易，被上海证监局出具警示函csrc.gov.cn
6. 6美迪西副总经理蔡金娜配偶短线交易，被上海证监局出具警示函nbd.com.cn